Default company panoramic image
117a2734 1a63 4998 ad5e 8a0ebc9f1eca

AM Biotechnologies

AM Biotechnologies develops DNA based affinity agents called X-aptamers, using proprietary technologies, as replacements for antibodies.

  • Stage Product In Development
  • Industry Biotechnology
  • Location Houston, TX, USA
  • Currency USD
  • Employees 10
  • Website

Company Summary

X-aptamers are chemically synthesized; they are stable in ambient environments with very long shelf life; and are rapidly produced in large quantities with easy quality control. We solve the problems associated with antibodies while delivering the same functionality. X-aptamers can be substituted for antibodies in virtually any application. We can develop thioaptamer affinity agents for your targets using our bead-based development service.


  • Default avatar
    Mark Shumbera

    Mr. Shumbera is the President of AM Biotechnologies, LLC as well as AptaMed, Inc. He formerly led MEI Technologies, Inc. Commercial Development Division where he built and managed MEI IP assets. While at MEI, Mr. Shumbera was responsible for establishing and assisting three start-up companies. He received a BS in Electrical Engineering from Texas A&M University and an MBA from The University of Houston Clear Lake.

  • Default avatar
    Xianbin Yang
    Director of R&D

    Dr. Yang is the Director of Research and Development for AM Biotechnologies. He specializes in nucleic acid chemistry and was the lead scientist in Dr. David Gorenstein’s laboratory at UTMB. Dr. Yang has unsurpassed technical knowledge of thioaptamers and their applications. He received his PhD in Bioorganic Chemistry from Polish Academy of Sciences, Lodz, Poland in 1998 and has over 44 publications in the field as well as 5 patents/patents pendi

  • Default avatar
    David Gorenstein
    Member - Board of Managers

    Dr. Gorenstein is the Deputy Director and Distinguished Chair of the Institute for Molecular Medicine at UT Health Science Center in Houston, Texas. He is also the Associate Dean for Research in the School of Medicine. Dr. Gorenstein holds over 35 patents (awarded and pending) on the synthesis of dithiophosphate oligonucleotide analogues and thiophosphate aptamer (“thioaptamer”) combinatorial selection technologies. He is a founder of AptaMed, In

  • Default avatar
    Tim McGrath
    Manager - Business Development

    Mr. McGrath is the Manager, Business Development for AM. As the former CEO of Xeotron he raised over $4M from corporate investors and managed the sale of Xeotron to Invitrogen. While President of Sigma-Genosys, sales grew from $2M to over $40M and he negotiated numerous licenses and marketing agreements. He managed the sale of Genosys to Sigma-Aldrich. Mr. McGrath has a B.S. in Zoology and an M.S. in Biochemistry from Texas A&M University.

Previous Investors

  • Default avatar
    MEI Technologies